- Home
- LBRDK vs HALO Comparison
LBRDK vs HALO Comparison
Compare LBRDK & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDK
- HALO
- Stock Information
- Founded
- LBRDK 2014
- HALO 1998
- Country
- LBRDK United States
- HALO United States
- Employees
- LBRDK N/A
- HALO N/A
- Industry
- LBRDK Cable & Other Pay Television Services
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LBRDK Telecommunications
- HALO Health Care
- Exchange
- LBRDK Nasdaq
- HALO Nasdaq
- Market Cap
- LBRDK 8.4B
- HALO 7.6B
- IPO Year
- LBRDK N/A
- HALO N/A
- Fundamental
- Price
- LBRDK $50.45
- HALO $68.24
- Analyst Decision
- LBRDK
- HALO Buy
- Analyst Count
- LBRDK 0
- HALO 11
- Target Price
- LBRDK N/A
- HALO $74.91
- AVG Volume (30 Days)
- LBRDK 1.0M
- HALO 2.2M
- Earning Date
- LBRDK 11-05-2025
- HALO 11-03-2025
- Dividend Yield
- LBRDK N/A
- HALO N/A
- EPS Growth
- LBRDK 1.38
- HALO 56.68
- EPS
- LBRDK 5.51
- HALO 4.74
- Revenue
- LBRDK $1,016,000,000.00
- HALO $1,242,852,000.00
- Revenue This Year
- LBRDK $8.37
- HALO $32.47
- Revenue Next Year
- LBRDK $2.91
- HALO $24.31
- P/E Ratio
- LBRDK $6.09
- HALO $14.41
- Revenue Growth
- LBRDK 306.40
- HALO 31.19
- 52 Week Low
- LBRDK $49.31
- HALO $42.01
- 52 Week High
- LBRDK $97.38
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- LBRDK 27.91
- HALO 56.09
- Support Level
- LBRDK $49.61
- HALO $67.40
- Resistance Level
- LBRDK $52.35
- HALO $66.97
- Average True Range (ATR)
- LBRDK 1.98
- HALO 2.04
- MACD
- LBRDK -0.53
- HALO 0.51
- Stochastic Oscillator
- LBRDK 11.97
- HALO 71.78
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.